<DOC>
	<DOCNO>NCT02886572</DOCNO>
	<brief_summary>The purpose study determine effectiveness efficiency Single Isocenter Multi-target Stereotactic Radiosurgery ( SIMT SRS ) patient four brain metastasis</brief_summary>
	<brief_title>SIMT Stereotactic Radiosurgery Outcomes Study</brief_title>
	<detailed_description>Forty patient four brain metastasis enrol prior radiosurgery . A planning MRI brain scan perform GD-DPTA within one week prior radiosurgery , per standard care . Neurocognitive ( Mini-Mental Status Examination ( MMSE ) , Trail-making test A &amp; B , Hopkins Learning Verbal ( HVLT ) ) functional assessment cancer therapy-brain ( FACT- Br ) obtain prior radiosurgery . Dose prescribe maximum isodose line encompass result PTV use dose guideline describe . The primary endpoint proportion patient live longer predict base diagnosis-specific GPA score . The Kaplan-Meier estimator use describe survival patient treat SIMT SRS . Secondary endpoint rate recurrence treat metastasis site , rate new brain metastasis site different SRS-treated metastasis site , rate death due neurological cause , prevalence significant adverse event . Exploratory endpoint include change time neurocognition quality life , quantification dosimetric measure , rate salvage therapy , rate radionecrosis SRS treatment site , rate intensity steroid-usage post-SRS . All patient evaluate neurocognitive function via MMSE , HVLT , Trail-making test A &amp; B , quality life via FACT-Br , local recurrence via MRI every 3 month course study . These evaluation do regular follow-up evaluation local recurrence suspect basis symptom . Distant recurrence define appearance new brain metastasis site different original metastasis . Recurrence define new area enhancement measure great 5 millimeter axial plane MRI . The length time recurrence original brain metastasis calculate date brain metastasis radiosurgery date recurrence detect MRI . Patients suspect recurrent tumor and/or symptomatic may undergo stereotactic biopsy evaluate radionecrosis versus recurrent brain metastasis , standard care .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<criteria>1 . A contrastenhanced MRI scan showing = &gt; 4 brain metastasis . 2 . Age &gt; /=18 year age . 3 . KPS &gt; /= 70 4 . Patient must grade prosnostic score ( GPA ) score 0.5 great 5 . Life expectancy least 3 month 6 . Postoperative patient resect brain metastasis eligible . 7 . Largest lesion &lt; 4cm diameter 8 . Must candidate MRI image 9 . Previous cranial stereotactic radiosurgery ( SRS ) whole brain radiation therapy ( WBRT ) allow &gt; 3 month prior SIMT 10 . Must capable providing inform consent 11 . The following histology include : breast , non small cell lung cancer ( NSCLC ) , gastrointestinal cancer ( GI ) , renal cell , melanoma 1 . Primary lesion radiosensitive histology ( i.e. , small cell carcinoma , germcell tumor , lymphoma , leukemia , multiple myeloma ) . 2 . Metastases within 2 mm optic apparatus 3 . Patients unable obtain MRI 4 . Evidence leptomeningeal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>